Literature DB >> 12860006

Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.

Animesh Pardanani1, Terra Reeder, Chin-Yang Li, Ayalew Tefferi.   

Abstract

Twenty to thirty-three percent of systemic mast cell disease (SMCD) patients have some degree of peripheral blood and/or bone marrow eosinophilia. While the clonality of SMCD was established by identification of the pathogenic c-kit Asp816 to Val (D816V) mutation in sorted cells of different hematopoietic lineages, this mutation has not previously been demonstrated in eosinophils from SMCD patients. In the current study, we demonstrate the D816V mutation in purified eosinophils from two patients with aggressive, eosinophilia-associated SMCD, thus proving that the eosinophils are clonal and not reactive in nature. The clinical implications of this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860006     DOI: 10.1016/s0145-2126(03)00065-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Authors:  Yoshiyuki Yamada; Jose A Cancelas
Journal:  Int Arch Allergy Immunol       Date:  2010-06-04       Impact factor: 2.749

Review 2.  Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells.

Authors:  Jennine Grootens; Johanna S Ungerstedt; Gunnar Nilsson; Joakim S Dahlin
Journal:  Blood Adv       Date:  2018-09-11

3.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

4.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.

Authors:  Hanneke C Kluin-Nelemans; Andreas Reiter; Anja Illerhaus; Bjorn van Anrooij; Karin Hartmann; Lambertus F R Span; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Alexander Zink; David Fuchs; Alex Kilbertus; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Dietger Niederwieser; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Lortholary; Thilo Jakob; Olivier Hermine; Julien Rossignol; Michel Arock; Jason Gotlib; Peter Valent; Wolfgang R Sperr
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

Review 5.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

Review 6.  Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Authors:  B M Jensen; C Akin; A M Gilfillan
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 7.  Novel targeted therapies for eosinophil-associated diseases and allergy.

Authors:  Susanne Radonjic-Hoesli; Peter Valent; Amy D Klion; Michael E Wechsler; Hans-Uwe Simon
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-17       Impact factor: 13.820

8.  ICON: Eosinophil Disorders.

Authors:  Peter Valent; Amy D Klion; Lanny J Rosenwasser; Michel Arock; Bruce S Bochner; Joseph H Butterfield; Jason Gotlib; Torsten Haferlach; Andrzej Hellmann; Hans-Peter Horny; Kristin M Leiferman; Georgia Metzgeroth; Kenji Matsumoto; Andreas Reiter; Florence Roufosse; Marc E Rothenberg; Hans-Uwe Simon; Karl Sotlar; Peter Vandenberghe; Peter F Weller; Gerald J Gleich
Journal:  World Allergy Organ J       Date:  2012-12       Impact factor: 4.084

9.  Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia.

Authors:  T L Lasho; C M Finke; D Zblewski; M Patnaik; R P Ketterling; D Chen; C A Hanson; A Tefferi; A Pardanani
Journal:  Blood Cancer J       Date:  2015-01-23       Impact factor: 11.037

10.  Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.

Authors:  Patricia Pautier; Clara Locher; Caroline Robert; Alain Deroussent; Caroline Flament; Axel Le Cesne; Annie Rey; Ratislav Bahleda; Vincent Ribrag; Jean-Charles Soria; Gilles Vassal; Alexander Eggermont; Laurence Zitvogel; Nathalie Chaput; Angelo Paci
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.